US EditionAlvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform
- Alvogen Pharma US, Inc. announced a definitive agreement to sell its parent company to Lotus Pharmaceutical Co., Ltd.
- Under the agreement, Alvogen will become a controlled subsidiary of Lotus, pending customary closing conditions.
- The integration is seen as a natural evolution of the partnership between Alvogen and Lotus, enhancing Alvogen's growth prospects.
- This acquisition highlights Alvogen's operational excellence and aims for sustainable growth in multiple segments.
30 Articles
30 Articles
The Berkshire Eagle
Alvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform
MORRISTOWN, N.J., Sept. 23, 2025 /PRNewswire/ -- Alvogen Pharma US, Inc. ("Alvogen"), a privately owned US-based pharmaceutical company, today announced a definitive agreement by its shareholders to sell its parent company to Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSE: 1795). Under…
One of the world's 20 largest generic companies will be created when Lotus Pharmaceutical acquires Alvogen. Alvogen's owners have approved Lotus's acquisition of all shares in Alvogen's parent company, New Alvogen Group Holdings.A statement from Aztiq, which has a large stake in Alvogen, says that this will give the company access to new markets in Asia and increased opportunities to advance in the United States. It also says that the value of t…
Alvogen Pharma in the United States, which is largely owned by Robert Wessman's investment firm, has been sold to Lotus in Taiwan, but the total value of the generic drug company in the transaction may amount to about two billion US dollars. This is Robert's second blockbuster of companies in the pharmaceutical sector where he takes a controlling stake in a few months.
Alvogen to be acquired by Lotus
MORRISTOWN, N.J. — Alvogen Pharma US, Inc. has entered into a definitive agreement for its shareholders to sell the company to Lotus Pharmaceutical Co., Ltd. Once complete, the transaction will make Alvogen a controlled subsidiary of Lotus, expanding the Taiwanese company’s global reach and U.S. presence.The deal deepens an existing collaboration between the two firms that has produced several successful co-developed launches. For Lotus, the acq…
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
